FDA approves the stent of Boston Scientific

Boston Scientific announced its next-generation drug-eluting stent was approved by the Federal Food and Drug Administration. With it’s innovative platinum chromium design, the PROMUS Element Plus Everolimus-Eluding Platinum Chromium Coronary Stent System offers enhanced visibility, less recoil, and higher radical strength. The clinical program PLATINUM of 1,800 worldwide patents proved the stent to be safe and effective. The stent is offered in a variety of sizes already, but Boston Scientific plans to widen the available stent sizes. Marketing plans are to begin immediately and the company expects to record $40 million in pre-tax charge in 2011’s fourth quarter.

 

SOURCE: Boston Scientific Press Release